There seem to be a lot of people here who like to kick the hell...

There seem to be a lot of people here who like to kick the hell out of Recce.
It would be really good if we could stay focused on the announcement.

Yes, getting a candidate to Phase 3 trials is proving to be a long process — but that's not unusual. Most biotech companies take 5 to 8 years on average from their starting point to Phase 3 commencement.

The difference with Recce (As pointed out by James), is that we're taking a portfolio approach to antibiotic development.That’s actually a smart move, as it arguably derisks the program somewhat compared to relying on a single clinical shot.

Back to the announcement itself:We now have two separate programs underway with the U.S. Army, which I think is fairly significant:

Burn Wound Infection Treatment (R327 Gel) – supported by a U.S. Department of Defense grant.
Cooperative Research and Development Agreement (CRADA) with the U.S. Army for broader pathogen testing.

If R327 proves active against highly infectious pathogens — such as resistant bacteria like Pseudomonas, MRSA, or Acinetobacter — the upside will be substantial.I would also like to think that if the U.S. Army sees real potential, they will expedite the program, just as we've seen happen in Indonesia, where authorities recognized the opportunity with R327 and moved quickly to engage.

this next 18-24months will be exciting